| Liu |
NCT06755151: Fenofibrate in Primary Biliary Cholangitis: a Real World Study |
|
|
| Recruiting | 3 | 300 | RoW | Fenofibrate | Xijing Hospital of Digestive Diseases | Primary Biliary Cholangitis (PBC) | 12/35 | 12/35 | | |
NCT06755541: Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study |
|
|
| Recruiting | 3 | 150 | RoW | Fenofibrate in Combination With Ursodeoxycholic Acid | Xijing Hospital of Digestive Diseases | Primary Biliary Cholangitis (PBC) | 12/35 | 12/35 | | |
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) |
|
|
| Recruiting | 3 | 320 | Europe, Canada, US, RoW | DZD9008, Pemetrexed+carboplatin | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 02/26 | 10/27 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL |
|
|
| Completed | 2 | 171 | US, RoW | AZD4205 | Dizal Pharmaceuticals | Relapsed or Refractory Peripheral T Cell Lymphoma | 10/23 | 02/24 | | |
NCT06175351: Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD). |
|
|
| Recruiting | 1/2 | 80 | RoW | 9MW1911, Placebo | Mabwell (Shanghai) Bioscience Co., Ltd. | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | 09/25 | 09/25 | | |
| Recruiting | 1 | 230 | US, RoW | DZD8586 | Dizal Pharmaceuticals | Lymphoma, Non-Hodgkin | 04/27 | 10/27 | | |
| Liu, Cheng-Wei |
| No trials found |
| Chang, Wei-Cheng |
| No trials found |
